Evidence map›Paper›PMID 32418156›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.

G Ingrosso, C Mariucci, M V Tenti, V Bini, E Alì, S Saldi, I Palumbo, R Bellavita, C Aristei

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

G IngrossoRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
C MariucciRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
M V TentiRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
V BiniInternal Medicine, Endocrine and Metabolic Science Section, University of Perugia, Perugia, Italy.
E AlìRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy. emanuele.ali.06@gmail.com.ORCID http://orcid.org/0000-0002-6196-5864
S SaldiRadiation Oncology Section, Perugia General Hospital, Perugia, Italy.
I PalumboRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
R BellavitaRadiation Oncology Section, Perugia General Hospital, Perugia, Italy.
C AristeiRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
University of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastasis-directed therapy (MDT) is an investigational treatment option in patients with oligorecurrent prostate cancer (PCa). The aim of this retrospective study is to report oncologic outcome and toxicity of elective nodal radiotherapy (ENRT) in PCa patients affected by pelvic nodal oligorecurrence.

methods41 consecutive patients were treated with salvage radiotherapy. At biochemical recurrence after primary treatment, oligorecurrent disease was detected by positron emission tomography (PET) in 94% of the patients. Image-guided intensity modulated radiation therapy (IMRT) was delivered using tomotherapy. 83% of the patients received androgen deprivation therapy (ADT) in combination with ENRT. Survival analysis was performed with Kaplan-Meier method, log-rank test was used to analyze associations between survival end-points and clinical parameters. Multivariate analysis was performed using Cox proportional hazards regression models. Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

resultsThe median at follow-up was 33.6 months. At 3 years, overall survival (OS), cancer-specific survival (CSS), and biochemical progression-free survival (b-PFS) were 89%, 92%, and 53%, respectively. At univariate analysis, all survival end-points were correlated with the number of positive pelvic lymph nodes at oligorecurrence (≤ 3 vs > 3). Biochemical-PFS was correlated with PSA (p = 0.034) and PSA doubling time (p = 0.004) at oligorecurrence. At multivariate analysis, no independent variable was statistically significant. No patient experienced grade ≥ 2 late toxicity after radiotherapy.

conclusionsThe number of metastatic lymph nodes and PSA doubling time seems to be important prognostic factors in the pelvic oligorecurrent setting. Salvage radiotherapy combined with short-course ADT might be a valid treatment strategy.

Indexed as

Lymphatic IrradiationAgedAndrogen AntagonistsCombined Modality TherapyHumansKaplan-Meier EstimateLymph NodesMaleMiddle AgedNeoplasm Recurrence, LocalPositron-Emission TomographyProgression-Free SurvivalProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesAndrogen AntagonistsProstate-Specific AntigenENRTOligorecurrent prostate cancerPelvic lymph nodesToxicity

Identifiers

PMID32418156
OpenAlexW3024793637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.